Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01859741 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
A Phase 1 study, sponsored by OncoMed Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 172
- Enrollment target
NCT01859741 is a Phase 1 study that was terminated before completion, run by OncoMed Pharmaceuticals. The registered enrollment target is 172 participants.
The verdict
NCT01859741, a Phase 1 study, was terminated before completion, sponsored by OncoMed Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 172 participants
- Enrollment target
Study Summary
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.
Interventions
- DRUG Placebo
- DRUG Etoposide
- DRUG Cisplatin or Carboplatin
- DRUG OMP-59R5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2012-01-07 |
| Est. Completion | 2017-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01859741
The ClinicalTrials.gov registry entry for NCT01859741 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01859741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01859741 about?
NCT01859741 is a clinical study titled "A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy". The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination...
What is the current status of trial NCT01859741?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 172 participants. The study started on 2012-01-07. Estimated completion is 2017-05-08.
What interventions are being tested in trial NCT01859741?
The interventions under investigation include: Placebo (DRUG), Etoposide (DRUG), Cisplatin or Carboplatin (DRUG), OMP-59R5 (DRUG).
Who is sponsoring clinical trial NCT01859741?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.